ApolloBio Corp. (NEEQ:430187) announced the initiation of a pre-clinical study for its novel broad-spectrum anti-COVID-19 nanobody, ABC-5100. The drug is designed to prevent or provide early treatment for SARS-CoV-2 coronavirus infections.
Pre-Clinical Study Details
ABC-5100 has demonstrated efficacy against various variants of concern (VOCs), including Omicron. The nanobody can be administered via nasal spray or aerosol inhalation, creating an antiviral immune barrier in the respiratory mucosa to prevent new infections and reduce viral levels and transmission risks post-infection.
Unique Advantages
With a unique antibody configuration and mechanism of action, ABC-5100 offers significant advantages over traditional IgG antibody drugs in terms of ease of use and patient compliance. The drug’s administration method provides a convenient and non-invasive approach to COVID-19 prevention and early treatment.
Previous Clinical Study
ApolloBio previously launched a Phase III clinical study for its DNA therapeutic vaccine ABC-3100, combined with the CELLECTRA 5PSP device, for HPV-16/18-related cervical high-grade squamous intraepithelial lesion (HSIL) in China.-Fineline Info & Tech
